Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients

Nephron - Clinical Practice

Volumn 121, Issue 3-4, 2013, Pages

  Albalate, M ^a   De La Piedra, C ^b   Ortiz, A ^c   Hernandez Perez J ^c   Rubert, M ^b   Perez Garcia R ^a   Zazo, P ^b   Nieto, L ^d   De Sequera, P ^a   Egido, J ^c  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b Department of Bioquímica ^*  (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^d Section of Nephrology   (Spain)

Author keywords

25 hydroxyvitamin D; Calcium; Haemodialysis; Phosphorus; PTH

Indexed keywords

1,25 HYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; CALCIFEDIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SPAIN; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84870310301     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000345148     Document Type: Article

References (29)

1. Rojas-Rivera J, De la Piedra C, Ramos A, Ortiz A, Egido J: The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: 2850-2865.
2. Melamed ML, Michos ED, Post W, Astor B: Calcifediol levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
3. Food and Nutrition Board of the Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D. Washington, National Academy Press, 2010.
4. Holick M, Bicnkley N, Bischoff-Ferrari H, Gordon C, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society: Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrin Metab 2011; 96: 1-20.
5. Muñoz-Torres M, Sosa Henríquez M: Situación actual de los niveles de vitamina D en la población española. Rev Española Enfermedades Metaból Óseas 2005; 14(suppl 1): 17-20.
6. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
7. Wagner D, Hanwell H, Vieth R: An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochemistry 2009; 42: 1549-1556.
8. Farrell CJ, Martin S, McWhinney B, Straub I, Williams P, Herrmann M: State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem 2012; 58: 531-542.
9. Jean G, Lafage-Proust MH, Massy ZA, Drüeke TB: Guidelines for vitamin D prescription in dialysis patients. Nephrol Ther 2009; 5: 520-532.
10. Clayton P, Singer R: 25-Hydroxyvitamin D levels in prevalent Australian dialysis patients. Nephrology 2009; 14: 554-559.
11. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515. (Pubitemid 29106838)
12. Torregrosa J, Bover J, Cannata Andía J, Lorenzo V, et al: Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseomineral en los pacientes con enfermedad renal crónica. Nefrología 2011; 31(suppl 1): 3-32.
13. KDIGO CKD-MBD Work Group: Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;suppl: S1-S130.
14. Dusso A, Tokumoto M: Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: 715-729.
15. Tolouian R, Rao DS, Goggins M, Bhat S, Gupta A: Seasonal variation of vitamin D in patients on hemodialysis. Clin Nephrol 2010; 74: 19-24.
16. Zerwekh JE: Blood biomarkers of vitamin D status. Am J Clin Nutr 2008; 87:1087S-1091S. (Pubitemid 351549268)
17. Matias P, Jorge C, Ferreira C, Borges M, et al: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911.
18. Nigwekar S, Bhan I, Thadhani R: Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 2012; 60: 139-156.
19. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4420.
20. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009; 24: 3799-3805.
21. Jean G, Terrat JC, Vanel T, Hurot JM, Lor riaux C, Mayor B, Chazot C: Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676.
22. Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008; 18: 375-382. (Pubitemid 351818240)
23. Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V: Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 2012; 95: 522-528.
24. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD: Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62.
25. Pérez-García R, Albalate M, de Sequera P, Alcázar R, Puerta M, Ortega M: Corchete. La hemodiafiltración en línea mejora la respuesta al tratamiento con calcifediol. Nefrología 2012; 32: 459-466.
26. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH: Evidence for extrarenal production of 1 alpha,25-dihydroxyvitamin D in man. J Clin Invest 1982; 69: 722-725. (Pubitemid 12184971)
27. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of se-rum 1,25-dihydroxycholecalciferol after months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008; 110: 58-65.
28. Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS: Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab 1984; 59: 1063-1069. (Pubitemid 15223338)
29. Heaney RP: Optimal vitamin D status. J Bone Miner Res 2009; 24: 755.